

Active substances set

Search phrase: carfilzomib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Multiple myeloma and plasma cell neoplasms

Carfilzomib

Carfilzomib in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO